Efficacy of S-1 in colorectal cancer

Bibliography

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, et al. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008;19:1600-4
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 2005;6:835-47
   PubMedGoogle Scholar
• Nishinari K, Wolosker N, Bernardi CV, Yazbek G. Totally implantable ports connected to valved catheters for chemotherapy: experience from 350 Groshong devices. J Vasc Access 2010;11:17-22
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57
   PubMed Web of Science ®Google Scholar
• Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72
   PubMedGoogle Scholar
• Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009;18:335-48
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141-5
   PubMed Web of Science ®Google Scholar
• Shirao K, Ohtsu A, Takada H, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-61
   PubMed Web of Science ®Google Scholar
• Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2-15
   PubMed Web of Science ®Google Scholar
• Yamada Y, Tahara M, Miya T, et al. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008;98:1034-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Cao C, Zhang Q, et al. Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis. PLoS One 2014;9:e84230
   PubMedGoogle Scholar
• Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 2012;13:1125-32
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013;14:1278-86
   PubMed Web of Science ®Google Scholar
• Goto A, Yamada Y, Yasui H, et al. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006;17:968-73
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Yuki S, Sogabe S, et al. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 2011;80:70-5
   PubMed Web of Science ®Google Scholar
• Shiozawa M, Akaike M, Sugano N, et al. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2010;66:987-92
   PubMed Web of Science ®Google Scholar
• Tsunoda A, Yasuda N, Nakao K, et al. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 2009;77:192-6
   PubMedGoogle Scholar
• Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60
   PubMed Web of Science ®Google Scholar
• Baba H, Watanabe M, Okabe H, et al. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br J Cancer 2012;107:1950-5
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Yuki S, Sogabe S, et al. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 2012;51:867-72
   PubMed Web of Science ®Google Scholar
• Mizushima T, Ide Y, Murata K, et al. A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer. Oncology 2013;85:317-22
   PubMedGoogle Scholar
• Yamada Y, Yamaguchi T, Matsumoto H, et al. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 2012;30:1690-6
   PubMed Web of Science ®Google Scholar
• Kato S, Andoh H, Gamoh M, et al. Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology 2012;83:101-7
   PubMedGoogle Scholar
• University Hospital Medical Information Network (UMIN). A. randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer (TRICOLORE). UMIN000007834. 2012. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000008819&language=J
   Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93
   PubMed Web of Science ®Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64
   PubMed Web of Science ®Google Scholar
• Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007;25:424-30
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Ishiguro M, Yoshida M, et al. Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: a randomized phase III trial (ACTS-CC). J Clin Oncol 2013;31(Suppl)):abstract 3518
   Google Scholar
• Mochizuki I, Takiuchi H, Ikejiri K, et al. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer 2012;106:1268-73
   PubMed Web of Science ®Google Scholar
• University Hospital Medical Information Network (UMIN). Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS). UMIN000003272. 2010. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000003940&language=J
   Google Scholar
• Takiuchi H, Tomita N, Boku N, et al. Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer. J Clin Oncol 2012;30(Suppl 4):abstract 572
   Google Scholar
• Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957-65
   PubMed Web of Science ®Google Scholar
• El Sayed YM, Sadee W. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Biochem Pharmacol 1982;31:3006-8
   PubMedGoogle Scholar
• Ikeda K, Yoshisue K, Matsushima E, et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000;6:4409-15
   PubMed Web of Science ®Google Scholar
• van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999;36:722-9
   PubMed Web of Science ®Google Scholar
• Yoshida R, Nakajima M, Nishimura K, et al. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003;74:69-76
   PubMed Web of Science ®Google Scholar
• Daigo S, Takahashi Y, Fujieda M, et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002;12:299-306
   PubMedGoogle Scholar
• Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006;80:282-97
   PubMed Web of Science ®Google Scholar
• Hirose T, Fujita K, Nishimura K, et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010;24:529-36
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403
   PubMed Web of Science ®Google Scholar
• Comets E, Ikeda K, Hoff P, et al. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 2003;30:257-83
   PubMed Web of Science ®Google Scholar
• Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118-23
   PubMed Web of Science ®Google Scholar
• Ichikawa W, Fujita K, Sasaki Y. The unanswered question: what is the determinant of S-1 pharmacokinetics? Clin Pharmacol Ther 2008;84:203; author reply 204
   PubMedGoogle Scholar